Coherus Oncology (CHRS) EV to FCF (2014 - 2026)

Coherus Oncology has disclosed EV to FCF across 13 years of filings, most recently posting 1.79 for Q2 2026.

• In Q2 2026, EV to FCF fell 410.81% year-over-year to 1.79; the TTM figure through Jun 2026 stood at 0.57 (down 39.26% YoY), while the FY2025 annual figure was 0.0, down 100.16% from the prior year.
• EV to FCF came in at 1.79 for Q2 2026 at Coherus Oncology, down from 1.62 in the prior quarter.
• In the past five years, EV to FCF ranged from a high of 1.17 in Q4 2024 to a low of 19.73 in Q4 2023.
• Average EV to FCF over 5 years is 4.16, with a median of 1.7 recorded in 2026.
• The largest YoY upside for EV to FCF was 106.26% in 2025 against a maximum downside of 561.45% in 2025.
• Over 5 years, EV to FCF stood at 4.33 in 2022, then slumped by 356.05% to 19.73 in 2023, then soared by 105.95% to 1.17 in 2024, then plunged by 99.74% to 0.0 in 2025, then sank by 59149.93% to 1.79 in 2026.
• Per Business Quant data, the three most recent EV to FCF figures were 1.79 in Q2 2026, 1.62 in Q1 2026, and 0.0 in Q4 2025.